NCI-H596Homo sapiens (Human)Cancer cell line
Also known as: NCIH596, NCI-HUT-596, H-596, H596
Quick Overview
Human lung cancer cell line with known mutations and drug sensitivity profiles.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1571 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lung[UBERON:UBERON_0002048] |
Donor Information
| Age | 73 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Lung adenosquamous carcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Lung Adenosquamous Carcinoma |
| OncoTree Code | LUAS |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000628_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Gly245Cys (c.733G>T) | Heterozygous | Somatic mutation acquired during proliferation | PubMed=18487078, PubMed=16020667, PubMed=15287027, PubMed=12884349, PubMed=1394225 |
| MutationSimple | RB1 | p.Ser182Ilefs*3 (c.542dupT) (c.541_542insT) | Heterozygous | - | Unknown, Unknown |
| MutationSimple | PIK3CA | p.Glu545Lys (c.1633G>A) | Heterozygous | - | from parent cell line MCF-7 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Comparative proteome analysis across non-small cell lung cancer cell lines.
Daub H.
J. Proteomics 130:1-10(2016).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A gene-alteration profile of human lung cancer cell lines.";
Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
Hum. Mutat. 30:1199-1206(2009).
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Oncogene 19:4632-4639(2000).
Mutation and expression of the DCC gene in human lung cancer.";
Yokota J.
Neoplasia 2:300-305(2000).
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Int. J. Oncol. 15:927-934(1999).
Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.
Lokshin A.E., Levitt M.L.
J. Cell. Biochem. Suppl. 24:186-197(1996).
NCI-Navy Medical Oncology Branch cell line data base.";
Carney D.N., Minna J.D., Mulshine J.L.
J. Cell. Biochem. Suppl. 24:32-91(1996).
Mutations and altered expression of p16INK4 in human cancer.";
Harris C.C.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
Neuromedin B is present in lung cancer cell lines.";
Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.
Cancer Res. 52:2732s-2736s(1992).
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Gazdar A.F.
Oncogene 7:171-180(1992).